盐酸洛美利嗪(Lomerizine Hydrochloride) - 药物靶点：calcium channel_在研适应症：偏头痛_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Lomerazine、Lomerizine、Lomerizine hydrochloride (JAN)

+ [6]

靶点

calcium channel

作用方式

抑制剂

作用机制

calcium channel抑制剂(钙通道抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Pfizer Japan, Inc.MSD KK

南京长澳医药科技有限公司

非在研机构

Merck & Co., Inc.

Santen Pharmaceutical Co., Ltd.

权益机构-

最高研发阶段批准上市

首次获批日期

日本 (1999-03-12),

偏头痛

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C27H30F2N2O3

InChIKeyJQSAYKKFZOSZGJ-UHFFFAOYSA-N

CAS号101477-55-8

查看全部结构式(2)

关联

4

项与盐酸洛美利嗪相关的临床试验

JPRN-jRCTs051220072

/ Not yet recruitingN/A

Effect of Lomerizine Hydrochloride on Preventing Recurrence of Cerebral Ischemic Events in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy - LOMCAD

开始日期2022-11-28

申办/合作机构-

JPRN-JapicCTI-183865

/ Unknown statusN/A

Administration study of lomerizine to healthy adult males

开始日期2018-02-14

申办/合作机构

LSI Medience Corp.

JPRN-jRCT1080223809

/ Unknown statusN/A

Administration study of lomerizine to healthy adult males

开始日期2018-02-14

申办/合作机构

LSI Medience Corp.

100 项与盐酸洛美利嗪相关的临床结果

登录后查看更多信息

100 项与盐酸洛美利嗪相关的转化医学

登录后查看更多信息

100 项与盐酸洛美利嗪相关的专利（医药）

登录后查看更多信息

248

项与盐酸洛美利嗪相关的文献（医药）

2024-12-01·Journal of Stroke and Cerebrovascular Diseases

Study protocol for LOMCAD Trial: Effect of lomerizine hydrochloride to prevent recurrence of cerebral ischemic events in CADASIL patients

Article

作者: Teramukai, Satoshi ; Fukunaga, Daiki ; Naito, Akari ; Watanabe-Hosomi, Akiko ; Nakata, Mitsuko ; Mizuno, Toshiki ; Ohara, Tomoyuki ; Mizuta, Ikuko ; Uno-Kadowaki, Aoi ; Matsuura, Hiraku ; Iwami, Yayoi ; Ito-Ihara, Toshiko

OBJECTIVESCerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is one of the most common monogenic cerebral small vessel diseases. Our previous observational study suggested that lomerizine hydrochloride, a calcium channel blocker approved in Japan in 1999 for the prevention of migraine headaches, is also effective for preventing recurrent ischemic stroke in CADASIL patients. The aim of this study (LOMCAD trial) is to verify the efficacy of lomerizine hydrochloride.MATERIALS AND METHODSThis is a multicenter, prospective, single-arm trial, using a historical control for comparison. CADASIL patients with a history of two or more cerebral ischemic events within the last two years will be administered lomerizine hydrochloride (5-mg tablet twice daily) for 24 months. The primary endpoint is symptomatic cerebral ischemic events during the 24-month period. Using our historical data and Bayesian sample size calculation based on a prior predictive distribution, the planned sample size was determined as 20 subjects.CONCLUSIONWe have planned a clinical trial to verify the effectiveness of lomerizine hydrochloride as prophylaxis to prevent recurrent cerebral ischemic events in CADASIL patients.REGISTRATIONThe LOMCAD trial has been registered in the Japan Registry of Clinical Trials (jRCTs051220072, https://jrct.niph.go.jp/latest-detail/jRCTs051220072).

2024-10-17·Cureus

A Case of Migraine Treated Through Hybrid Consultation via In-Person and Online Telemedicine at an Occupational Health Nurse’s Office

Article

作者: Ooka, Miho ; Katsuki, Masahito ; Sato, Daiki ; Wada, Yasuhiro ; Nakata, Yuki

An occupational doctor cannot perform medical procedures, such as diagnosis and prescription. They can only give advice to the workplace. Online telemedicine facilitates workplace-doctor collaboration and may solve this problem. We present the first case of migraine treated by hybrid consultation via in-person and online telemedicine at the occupational health office. In the present case, a 36-year-old male had experienced headaches since age 15 and had been diagnosed with migraine. He was on prophylactic treatment with 10 mg of lomerizine, experiencing one monthly migraine attack, often relieved by 50 mg of sumatriptan. His Headache Impact Test-6 (HIT-6) score was 56 at the consultation. He visited the occupational health nurse's office due to a migraine attack. An occupational doctor assessed him and diagnosed a migraine attack. The patient requested triptans, but only over-the-counter acetaminophen was available, and the doctor could not prescribe medication because the doctor was just an occupational doctor, and the nurse's office was not a clinic under the Japanese Medical Act. The occupational doctor, who was also hired by the other clinic as a physician, conducted an online consultation via the clinic at the nurse's office, diagnosed a migraine attack, and prescribed 50 mg of sumatriptan. The prescription was sent to a nearby pharmacy, and the patient found relief within 15 minutes after taking the triptan. Regular online consultation at the nurse's office has been continued, and prophylactic medications were strengthened. His migraine frequency decreased once in five months, and the HIT-6 score improved to 50. Performing online telemedicine at the workplace, such as the occupational nurse's office, could overturn the conventional wisdom that occupational physicians cannot perform medical treatment at non-medical institutions and can only refer patients to other clinics based on the Japanese Medical Act. Our case suggested the importance of strategic collaboration between occupational doctors and telemedicine-enabled medical facilities in ensuring seamless healthcare delivery, particularly for busy workers.

2024-09-09·Angewandte Chemie International Edition

Development of Iron‐Based Single Atom Materials for General and Efficient Synthesis of Amines

Article

作者: Zbořil, Radek ; Kreyenschulte, Carsten ; Menezes, Prashanth W. ; Bartling, Stephan ; Kuloor, Chakreshwara ; Ma, Zhuang ; Haumann, Michael ; Beller, Matthias ; Jagadeesh, Rajenahally V. ; Malina, Ondrej

AbstractEarth abundant metal‐based heterogeneous catalysts with highly active and at the same time stable isolated metal sites constitute a key factor for the advancement of sustainable and cost‐effective chemical synthesis. In particular, the development of more practical, and durable iron‐based materials is of central interest for organic synthesis, especially for the preparation of chemical products related to life science applications. Here, we report the preparation of Fe‐single atom catalysts (Fe‐SACs) entrapped in N‐doped mesoporous carbon support with unprecedented potential in the preparation of different kinds of amines, which represent privileged class of organic compounds and find increasing application in daily life. The optimal Fe‐SACs allow for the reductive amination of a broad range of aldehydes and ketones with ammonia and amines to produce diverse primary, secondary, and tertiary amines including N‐methylated products as well as drugs, agrochemicals, and other biomolecules (amino acid esters and amides) utilizing green hydrogen.

100 项与盐酸洛美利嗪相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02633	盐酸洛美利嗪	N02C	DB14065

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
偏头痛	日本	Pfizer Japan, Inc.	1999-03-12

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脑梗塞	临床2期	日本	-	-
青光眼	临床前	日本	-	2003-08-24

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ARVO2014	N/A	开角型青光眼 \| 青光眼	120	Lomerizine 10 mg	鹹鹹選鬱繭觸蓋蓋窪糧(製積願鹹襯製衊網構製) = 鬱製艱鹽蓋醖簾範構廠鏇廠範鏇製廠齋夢醖築 (簾醖廠淵鏇積齋願遞範 )	积极	2014-04-01
				Methylcobalamin 1500 μg	鹹鹹選鬱繭觸蓋蓋窪糧(製積願鹹襯製衊網構製) = 網淵糧廠壓襯鬱糧範範鏇廠範鏇製廠齋夢醖築 (簾醖廠淵鏇積齋願遞範 )
ARVO2010	N/A	-	9	Nilvadipine	願壓積鏇糧獵繭鏇顧願(鏇鹽襯繭選顧膚築壓淵) = 夢繭齋襯憲築鏇齋壓餘齋蓋觸憲醖淵糧製衊簾 (膚獵積顧顧窪糧積構襯 )	-	2010-04-01
				Lomerizine	願壓積鏇糧獵繭鏇顧願(鏇鹽襯繭選顧膚築壓淵) = 壓壓製繭衊膚醖壓觸遞齋蓋觸憲醖淵糧製衊簾 (膚獵積顧顧窪糧積構襯 )
ARVO2003	N/A	视神经损伤	-	Vehicle-treated group	鑰願廠構餘鬱蓋觸鏇鬱(鬱鹽遞鏇簾夢鹽製醖獵) = 觸範鹽窪淵築顧鹽憲鬱簾築遞簾繭壓廠窪簾網 (鏇鑰廠齋顧製觸網壓鹽 )	积极	2003-05-01
				Lomerizine 10 mg/kg	鑰願廠構餘鬱蓋觸鏇鬱(鬱鹽遞鏇簾夢鹽製醖獵) = 網願簾鏇膚網簾蓋憲衊簾築遞簾繭壓廠窪簾網 (鏇鑰廠齋顧製觸網壓鹽 )